Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lower Lead Limits For Calcium-Containing Products Shelved By FDA

This article was originally published in The Tan Sheet

Executive Summary

FDA is not adopting new, lower lead limits for calcium-containing supplements and antacids at this time but "is actively investigating the feasibility of establishing lower limits," the agency tells the Council for Responsible Nutrition and the Consumer Healthcare Products Association in a Sept. 28 letter.
Advertisement

Related Content

Calcium Supplementation May Benefit Lead Levels - JAMA Editorial
Calcium Supplementation May Benefit Lead Levels - JAMA Editorial
Calcium Supplementation May Benefit Lead Levels - JAMA Editorial
USP Supplement Potency Lower Limit Of 90% Retained
USP Supplement Potency Lower Limit Of 90% Retained
USP Supplement Potency Lower Limit Of 90% Retained
Calcium lead limit sought by NRDC "not scientifically defensible" or "feasible," FDA told.
Calcium lead limit sought by NRDC "not scientifically defensible" or "feasible," FDA told.
Lead limits in calcium supplements, antacids requested in NRDC citizen petition.

Topics

Advertisement
UsernamePublicRestriction

Register

PS090471

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel